Angela Arenas-Gamboa, DVM, PhD, DACVP

Angela Arenas-Gamboa, DVM, PhD, DACVP

Assistant Professor


Department of Molecular and Cellular Medicine
Room 425 Reynolds Medical Building
College Station, TX   77840

Phone: 979.862.7537
Fax: 979.847.9481
amarenas@medicine.tamhsc.edu

Education and Post-Graduate Training

Dr. Angela Arenas is an assistant professor of molecular and cellular medicine. Arenas received her DVM from the University of La Salle in Colombia in 2002 and her PhD in veterinary microbiology from Texas A&M University in 2007 in the laboratory of Drs. Thomas and Allison Ficht. Her research focused on the development of Brucella vaccines for human and animal use. From 2007 to 2010 she completed her residency in veterinary anatomic pathology at the College of Veterinary Medicine at Texas A&M University. She received her DACVP in veterinary anatomic pathology from the American College of Veterinary Pathology in 2010. Before joining the Texas A&M faculty in 2011 she was an assistant research scientist in the laboratory of Dr. Allison Ficht at the Texas A&M Health Science Center from 2007-2011. 

Research Interests

My laboratory is interested in the development of vaccines against select agents focusing on Brucella spp. We incorporate the microencapsulation technology to increase safety and efficacy of vaccines for human and animal use. These studies are principally targeted on the understanding of the response to infection by the host and elucidating the correlates of protective immunity elicited by the encapsulated and non-encapsulated vaccines.

Selected Publications

Arenas-Gamboa AM, Mansell J. Epithelioid haemangiosarcoma in the ocular tissue of horses. J Comp Pathol. 2011 May;144(4):328-33. Epub 2011 Jan 19.

Polymeric particles in vaccine delivery.Rice-Ficht AC, Arenas-Gamboa AM, Kahl-McDonagh MM, Ficht TA. Curr Opin Microbiol. 2010 Feb;13(1):106-12. Epub 2010 Jan 14. Review.

Arenas-Gamboa AM, Ficht TA, Davis DS, Elzer PH, Kahl-McDonagh M, Wong-Gonzalez A, et al. Oral vaccination with microencapsuled strain 19 vaccine confers enhanced protection against Brucella abortus strain 2308 challenge in red deer (Cervus elaphus elaphus). J WiIdl Dis. 2009;45(4): 1021-1029.  

Ficht TA, KahI-McDonagh MM, Arenas-Gamboa AM, Rice-Ficht AC. Brucellosis: the case for live, attenuated vaccines. Vaccine. 2009;27 Suppl 4:D40-43.  

Arenas-Gamboa AM, Ficht TA, Davis DS, Elzer PH, Wong-Gonzalez A, Rice-Ficht AC. Enhanced immune response of red deer (Cervus elaphus) to live rb5i vaccine strain using composite microspheres. J WildI Dis. 2009;45(1 ): 165-173.

Arenas-Gamboa AM, Ficht TA, Kahl-McDonagh MM, Gomez G, Rice-Ficht, A.C.

The Brucella abortus Si 9 DeltavjbR live vaccine candidate is safer than Si 9 and confers protection against wild-type challenge in BALB/c mice when delivered in a sustained-release vehicle. Infect Immun. 2009; 77(2):877-884.  

Arenas-Gamboa AM, Ficht TA, Kahl-McDonagh MM, Rice-Ficht AC. Immunization with a single dose of a microencapsulated Brucella melitensis mutant enhances protection against wild-type challenge. Infect Immun. 2008;76(6):2448-2455.

Kahl-McDonagh MM, Arenas-Gamboa AM, Ficht TA. Aerosol infection of BALB/c mice with Brucella melitensis and Brucella abortus and protective efficacy against aerosol challenge. Infect lmmun. 2007;75(10):4923-4932